Scientific Article|Articles in Press

Results of Implementation of Amyloidosis Screening for Patients Undergoing Carpal Tunnel Release

Published:January 14, 2023DOI:


      Many patients with amyloidosis undergo carpal tunnel release (CTR) before amyloidosis diagnosis and before developing cardiac or other serious disease manifestations. The purposes of this study were to examine if our patient population had a similar prevalence of positive amyloidosis diagnoses to that in prior studies and to describe the results of implementing a screening program for amyloidosis.


      We retrospectively reviewed the biopsy results and subsequent interventions for all patients who underwent screening tenosynovial biopsy during CTR from March 2020 through December 2021. Amyloid screening was offered to patients who met the criteria for increased risk of disease using an appropriateness screening algorithm.


      Seventy-five (48%) of 156 patients who underwent CTR met the eligibility criteria for amyloidosis testing. Of the 62 patients who agreed to undergo tenosynovial biopsy, 14 had amyloid-positive biopsy specimens (10 men and 4 women). All patients with positive tenosynovial biopsies had bilateral carpal tunnel syndrome and wild-type transthyretin amyloid subtype. One patient was diagnosed and started treatment for otherwise asymptomatic cardiac amyloidosis.


      The incidence of amyloid-positive tenosynovial biopsy results from CTR was 22.5% in patients using the criteria from an appropriateness screening algorithm, which was higher than previously reported. Implementation of a screening program for patients undergoing CTR requires a multidisciplinary approach and may result in early diagnosis and lifesaving interventions for patients with amyloidosis.

      Type of study/level of evidence

      Differential diagnosis/symptom prevalence study, II.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Hand Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fajardo M.
        • Kim S.H.
        • Szabo R.M.
        Incidence of carpal tunnel release: trends and implications within the United States ambulatory care setting.
        J Hand Surg Am. 2012; 37: 1599-1605
        • Cranford C.S.
        • Ho J.Y.
        • Kalainov D.M.
        • Hartigan B.J.
        Carpal tunnel syndrome.
        J Am Acad Orthop Surg. 2007; 15: 537-548
        • Kyle R.A.
        • Eilers S.G.
        • Linscheid R.L.
        • Gaffey T.A.
        Amyloid localized to tenosynovium at carpal tunnel release. Natural history of 124 cases.
        Am J Clin Pathol. 1989; 91: 393-397
        • Sueyoshi T.
        • Ueda M.
        • Jono H.
        • et al.
        Wild-type transthyretin-derived amyloidosis in various ligaments and tendons.
        Hum Pathol. 2011; 42: 1259-1264
        • Sekijima Y.
        • Uchiyama S.
        • Tojo K.
        • et al.
        High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly.
        Hum Pathol. 2011; 42: 1785-1791
        • Falk R.H.
        Diagnosis and management of the cardiac amyloidoses.
        Circulation. 2005; 112: 2047-2060
        • Nakagawa M.
        • Sekijima Y.
        • Yazaki M.
        • et al.
        Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis.
        Amyloid. 2016; 23: 58-63
        • Milandri A.
        • Farioli A.
        • Gagliardi C.
        • et al.
        Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies.
        Eur J Heart Fail. 2020; 22: 507-515
        • Grogan M.
        • Dispenzieri A.
        Natural history and therapy of AL cardiac amyloidosis.
        Heart Fail Rev. 2015; 20: 155-162
        • Grogan M.
        • Dispenzieri A.
        • Gertz M.A.
        Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response.
        Heart. 2017; 103: 1065-1072
        • Grogan M.
        • Scott C.G.
        • Kyle R.A.
        • et al.
        Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system.
        J Am Coll Cardiol. 2016; 68: 1014-1020
        • Lane T.
        • Fontana M.
        • Martinez-Naharro A.
        • et al.
        Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis.
        Circulation. 2019; 140: 16-26
        • Ravichandran S.
        • Lachmann H.J.
        • Wechalekar A.D.
        Epidemiologic and survival trends in amyloidosis, 1987-2019.
        N Engl J Med. 2020; 382: 1567-1568
        • Sperry B.W.
        • Reyes B.A.
        • Ikram A.
        • et al.
        Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release.
        J Am Coll Cardiol. 2018; 72: 2040-2050
        • DiBenedetto M.
        • Soong M.
        • Hunter A.
        • Tolo E.
        • Clair B.
        • Kasparyan N.G.
        Prevalence and subtypes of tenosynovial amyloid in patients undergoing carpal tunnel release.
        J Hand Surg Am. 2022; 47: 540-543
        • Sood R.F.
        • Kamenko S.
        • McCreary E.
        • et al.
        Diagnosing systemic amyloidosis presenting as carpal tunnel syndrome: a risk nomogram to guide biopsy at time of carpal tunnel release.
        J Bone Joint Surg Am. 2021; 103: 1284-1294
        • Fosbøl E.L.
        • Rørth R.
        • Leicht B.P.
        • et al.
        Association of carpal tunnel syndrome with amyloidosis, heart failure, and adverse cardiovascular outcomes.
        J Am Coll Cardiol. 2019; 74: 15-23
        • Rubin J.
        • Maurer M.S.
        Cardiac amyloidosis: overlooked, underappreciated, and treatable.
        Annu Rev Med. 2020; 71: 203-219
        • Donnelly J.P.
        • Hanna M.
        • Sperry B.W.
        • Seitz W.H.
        Carpal tunnel syndrome: a potential early, red-flag sign of amyloidosis.
        J Hand Surg Am. 2019; 44: 868-876
        • Ton V.K.
        • Mukherjee M.
        • Judge D.P.
        Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction.
        Clin Med Insights Cardiol. 2014; 8: 39-44
        • Aus dem Siepen F.
        • Hein S.
        • Prestel S.
        • et al.
        Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?.
        Clin Res Cardiol. 2019; 108: 1324-1330
        • Ladabaum U.
        • Dominitz J.A.
        • Kahi C.
        • Schoen R.E.
        Strategies for colorectal cancer screening.
        Gastroenterology. 2020; 158: 418-432
        • Maurer M.S.
        • Schwartz J.H.
        • Gundapaneni B.
        • et al.
        Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.
        N Engl J Med. 2018; 379: 1007-1016
        • Sood R.F.
        • Lipira A.B.
        Risk of amyloidosis and heart failure among patients undergoing surgery for trigger digit or carpal tunnel syndrome: a nationwide cohort study with implications for screening.
        J Hand Surg Am. 2022; 47 (e4): 517-525